# Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201

> **NCT00230490** · PHASE2 · TERMINATED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 150 (—)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** pradefovir mesylate
- **DRUG:** adefovir dipivoxyl

## Key facts

- **NCT ID:** NCT00230490
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-06
- **Primary completion:** —
- **Final completion:** 2007-05
- **Target enrollment:** 150 (—)
- **Why stopped:** Adverse findings from nonclinical carcinogenicity studies.
- **Last updated:** 2019-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00230490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00230490, "Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00230490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*